NYSE:PFEPharmaceuticals
Assessing Pfizer (PFE) Valuation After Bearish Analyst Rating And COVID Vaccine Trial Pause
Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-19 vaccine trial adds to short term uncertainty.
See our latest analysis for Pfizer.
Despite the latest bearish commentary and trial pause weighing on sentiment in recent days, Pfizer’s share price shows a 9.1% year to date share price return and a 31.0% total shareholder return over the past...